The stock market has taken some hits so far in 2022, but this move lower has opened up opportunities to buy up high-quality stocks at discount prices.And there are 3 undervalued stocks to buy this week that can outperform over the years to come.
Shah Gilani has the tickers for the two best stocks to trade right now..
"Sell in May and go away" might be popular advice.
But it could cost you if you sell your entire portfolio.
But leaving these toxic stocks in won't be any better.
You could forgive drug and biotech executives for having a bad case of target fixation.
After all, they do work in a field that is filled with time-consuming and expensive headaches.
Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.
The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.
With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.
And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.
It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.
The Dow Jones Industrial Average will not see much growth today, as a number of big Dow components are feeling the impacts of the U.S.-China trade war.
Many blame the trade war between the United States and China on lower sales, higher shipping costs.
With recession indicators flashing, investors are flocking to 10-year bonds that have the annual upside of just 1.5%.
But there are still market-beating stocks out there – in fact, one of our picks expects 103% growth.
And that brings us to the biotech industry.
There are some big biotech stocks to own right now that could deliver double, even triple-digit upside in less than 12 months.
Things that'll be "different this time" usually aren't, especially when it comes to hot stoves, hot steering wheels, and hot bond markets. Touch 'em and you'll get burned, or so goes the thinking.
Every once in a while, though, the situation plays out.
Take the inverted yield curve that caused last Friday's vicious selloff and made countless headlines around the world when it happen for the first time since 2007.
Contrary to what Wall Street and legions of economists want you to believe, it may NOT be the harbinger of doom that it's been for the past 50 years.
Here's my case (and what to buy if you're interested in big profits)…
The Dow Jones today might see a triple-digit slip as investors digest the latest weekly jobless report and ongoing concerns about global economic growth.
Markets also did not rally after the Federal Reserve announced it would remain dovish on interest rates through the end of 2019.
Biotech companies are known for their potential to break out when a new drug comes to market, and today we're giving you two of the best biotech stocks to buy now.
Buying the top biotech stocks offers the sort of upside that's so hard to find right now.
At the end of 2018, the Federal Reserve told the market the water was warm, come in for a swim.
The market was happy to oblige. In fact, the S&P 500 has rebounded almost 11% to start 2019, nearly erasing all of the losses from December.
It's as if the sell-off never happened.